RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Antibe Therapeutics Stock

Antibe Therapeutics P/E 2024

Antibe Therapeutics P/E

-0.68

Ticker

ATE.TO

ISIN

CA0370255097

WKN

A2QJPN

As of Sep 30, 2024, Antibe Therapeutics's P/E ratio was -0.68, a -50.36% change from the -1.37 P/E ratio recorded in the previous year.

The Antibe Therapeutics P/E history

Antibe Therapeutics Aktienanalyse

What does Antibe Therapeutics do?

Antibe Therapeutics Inc is a biopharmaceutical company specializing in the development of novel treatment methods for inflammation and pain. The Canadian company was founded in 2009 and is headquartered in Toronto, Ontario. Antibe Therapeutics has made a name for itself in the pharmaceutical industry through its innovative technologies and compounds. The business model of Antibe Therapeutics is based on the discovery and development of new compounds based on non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are among the most commonly used medications for the treatment of inflammation and pain. However, Antibe Therapeutics has developed a promising method to optimize the compounds of NSAIDs and minimize their side effects. The company is divided into three divisions to organize its products and services. The first division is the analgesic pipeline, which focuses on the research and development of neuromodulation programs for the treatment of pain and inflammation. Antibe Therapeutics' neuromodulation technology aims to target specific receptor systems to treat inflammation and pain specifically. The second division is the GI Safety Inhibition Concept, which offers a novel anti-inflammatory technology for the treatment of pain and inflammation with improved gastrointestinal tolerability. This technology aims to minimize the side effects of NSAIDs, particularly in the gastrointestinal system. The third division is the clinical development, which conducts clinical trials for new medications. Antibe Therapeutics has a number of drugs in clinical development, including ATB-346, which is considered a novel anti-inflammatory and pain-reducing medication for patients with arthritis and other inflammatory conditions. Another important product of Antibe Therapeutics is the fully synthesized hydroxyliminodiazole molecule (ATB-352), which is used for the treatment of neuropathic pain. The company believes that ATB-352 offers promising benefits over conventional pain medications and represents an effective treatment option for patients with chronic pain. Antibe Therapeutics has established several partnerships with major pharmaceutical companies in the past to advance the development and commercialization of its products. In 2020, Antibe Therapeutics entered into an agreement with Nuance Pharma, a leading Chinese company in the development and commercialization of anesthetics, to market ATB-346 in China and adjacent areas. This partnership provides Antibe Therapeutics with access to the rapidly growing markets in Asia and also strengthens its position as a global company. Overall, Antibe Therapeutics has found a valuable place in the pharmaceutical industry through its innovation and ability to focus on the areas of inflammation and pain. With a strong pipeline and a variety of promising product candidates, Antibe Therapeutics believes it is able to improve the lives of millions of people worldwide by providing safer and more effective treatment methods for inflammation and pain. Antibe Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Antibe Therapeutics's P/E Ratio

The Price to Earnings (P/E) Ratio of Antibe Therapeutics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Antibe Therapeutics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Antibe Therapeutics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Antibe Therapeutics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Antibe Therapeutics stock

What is the price-to-earnings ratio of Antibe Therapeutics?

The price-earnings ratio of Antibe Therapeutics is currently -0.68.

How has the price-earnings ratio of Antibe Therapeutics changed compared to last year?

The price-to-earnings ratio of Antibe Therapeutics has increased by -50.36% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Antibe Therapeutics high compared to other companies?

Yes, the price-to-earnings ratio of Antibe Therapeutics is high compared to other companies.

How does an increase in the price-earnings ratio of Antibe Therapeutics affect the company?

An increase in the price-earnings ratio of Antibe Therapeutics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Antibe Therapeutics affect the company?

A decrease in the price-earnings ratio of Antibe Therapeutics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Antibe Therapeutics?

Some factors that influence the price-earnings ratio of Antibe Therapeutics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Antibe Therapeutics pay?

Over the past 12 months, Antibe Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Antibe Therapeutics is expected to pay a dividend of 0 CAD.

What is the dividend yield of Antibe Therapeutics?

The current dividend yield of Antibe Therapeutics is .

When does Antibe Therapeutics pay dividends?

Antibe Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Antibe Therapeutics?

Antibe Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Antibe Therapeutics?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Antibe Therapeutics located?

Antibe Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Antibe Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Antibe Therapeutics from 9/30/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/30/2024.

When did Antibe Therapeutics pay the last dividend?

The last dividend was paid out on 9/30/2024.

What was the dividend of Antibe Therapeutics in the year 2023?

In the year 2023, Antibe Therapeutics distributed 0 CAD as dividends.

In which currency does Antibe Therapeutics pay out the dividend?

The dividends of Antibe Therapeutics are distributed in CAD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Antibe Therapeutics

Our stock analysis for Antibe Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Antibe Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.